Giulia Veronesi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giulia Veronesi has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Lorenzo Spaggiari
Department of Oncology and Hemato-oncology, University of Milan, 20122 Milan, Italy
21 shared publications - Patrick Maisonneuve
Division of Epidemiology and Biostatistics IEO European Institute of Oncology IRCCS Milan Italy
11 shared publications - Piergiorgio Solli
Thoracic Surgery Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
10 shared publications Giuseppe Pelosi
School of Medicine, University of Milan, Milan, Italy
9 shared publicationsMarco Alloisio
8 shared publicationsMassimo Bellomi
Dept of Radiological Science and Radiation Therapy, European Institute of Oncology, Milan, Italy Dept of Health Sciences, University of Milan, Milan, Italy
8 shared publications
Latest Publications
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 675
Left basilar segmentectomy
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5 (1) , 674
Apical segmentectomy of the left lower lobe
Apical segmentectomy of the left lower lobe
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5 (1) , 674
Apical segmentectomy of the left lower lobe
Apical segmentectomy of the left lower lobe
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 672
Right upper lobe posterior segmentectomy
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 672
Right upper lobe posterior segmentectomy
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 673
Lingula sparing left upper lobectomy
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 673
Lingula sparing left upper lobectomy
- 1 August 2018
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 4, 166
Robotic-assisted pulmonary segmentectomies
The increased detection of early non-small cell lung cancers (NSCLCs) has allowed many surgeons to consider treatment of small peripheral lesions with intentional limited resection, which has gained much interest even in patients with low surgical risk. The minimally invasive approach to lung surgery has many benefits that have been widely reported. Robotic-assisted thoracoscopic surgery, similar to video-assisted thoracoscopic surgery (VATS), for lung cancer offers several advantages, including improved visualization and more precise instrument manipulation. Minimally invasive segmentectomy combines two beneficial aspects: first, the decreased surgical insult to the patient; second, the concept of “lung-sparing surgery”, especially for those patients with reduced lung function. We report here a review of the literature about robotic-assisted segmentectomies. We will then describe the technique for specific segmentectomies, with related tips, tricks, and pitfalls.
- 1 August 2018
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 4, 166
Robotic-assisted pulmonary segmentectomies
The increased detection of early non-small cell lung cancers (NSCLCs) has allowed many surgeons to consider treatment of small peripheral lesions with intentional limited resection, which has gained much interest even in patients with low surgical risk. The minimally invasive approach to lung surgery has many benefits that have been widely reported. Robotic-assisted thoracoscopic surgery, similar to video-assisted thoracoscopic surgery (VATS), for lung cancer offers several advantages, including improved visualization and more precise instrument manipulation. Minimally invasive segmentectomy combines two beneficial aspects: first, the decreased surgical insult to the patient; second, the concept of “lung-sparing surgery”, especially for those patients with reduced lung function. We report here a review of the literature about robotic-assisted segmentectomies. We will then describe the technique for specific segmentectomies, with related tips, tricks, and pitfalls.
- 1 May 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 517
Four arms robotic left upper lobectomy performed with da Vinci Xi System
- 1 May 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 517
Four arms robotic left upper lobectomy performed with da Vinci Xi System
- Open Access
- 1 January 2018
- Published by AME Publishing Company in Shanghai Chest
- Vol. 2 (9) , 68
Robotic innovations (instruments and new robots)
- 1 January 2018
- Published by AME Publishing Company in Shanghai Chest
- Vol. 2 (9) , 68
Open AccessRobotic innovations (instruments and new robots)
- 1 September 2017
- Published by AME Publishing Company in ASVIDE
- Vol. 4 (1) , 431
Main surgical passages of robotic resection of a thymoma involving the left anonymous vein, the left phrenic nerve and lung parenchyma of left upper lobe
- 1 September 2017
- Published by AME Publishing Company in ASVIDE
- Vol. 4 (1) , 431
Main surgical passages of robotic resection of a thymoma involving the left anonymous vein, the left phrenic nerve and lung parenchyma of left upper lobe
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Implication of Filamin A in pulmonary neuroendocrine tumors aggressiveness and progression
Pulmonary neuroendocrine tumors (PNTs) comprise a spectrum of neoplasms, ranging from low grade carcinoids to the highly malignant small cell lung cancers. Several studies identified cytoskeleton protein Filamin A (FLNA) as determinant in cancer progression and metastasis. To date, the role of FLNA in PNTs aggressiveness and progression is still unknown. To address this question, we decided: i) to evaluate FLNA expression in PNTs ranging from typical carcinoids to small cell lung carcinomas; ii) to manipulate FLNA expression in order to assess its possible influence on cell proliferation, cell adhesion and migration in PNTs cell lines (H727 cells) and primary cultures; iii) to focus on the possible interaction between FLNA and Rap1, a small GTPase implicated in the regulation of cell polarity and migration. FLNA is highly expressed in PNTs with high malignant grade, this expression being the highest in small cell lung carcinomas. Interestingly, FLNA silencing reduces cyclin D1 levels in PNTs cells and H727 cells (−53±3 PPPPPP<0,01 vs C-siRNA). In conclusion, these results demonstrated that FLNA is involved in mediating PNT progression thus providing a possible diagnostic and therapeutic target.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Implication of Filamin A in pulmonary neuroendocrine tumors aggressiveness and progression
Pulmonary neuroendocrine tumors (PNTs) comprise a spectrum of neoplasms, ranging from low grade carcinoids to the highly malignant small cell lung cancers. Several studies identified cytoskeleton protein Filamin A (FLNA) as determinant in cancer progression and metastasis. To date, the role of FLNA in PNTs aggressiveness and progression is still unknown. To address this question, we decided: i) to evaluate FLNA expression in PNTs ranging from typical carcinoids to small cell lung carcinomas; ii) to manipulate FLNA expression in order to assess its possible influence on cell proliferation, cell adhesion and migration in PNTs cell lines (H727 cells) and primary cultures; iii) to focus on the possible interaction between FLNA and Rap1, a small GTPase implicated in the regulation of cell polarity and migration. FLNA is highly expressed in PNTs with high malignant grade, this expression being the highest in small cell lung carcinomas. Interestingly, FLNA silencing reduces cyclin D1 levels in PNTs cells and H727 cells (−53±3 PPPPPP<0,01 vs C-siRNA). In conclusion, these results demonstrated that FLNA is involved in mediating PNT progression thus providing a possible diagnostic and therapeutic target.
- Open Access
- 24 November 2015
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 9, 597
Chemoprevention studies within lung cancer screening programmes
Ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epide
- 24 November 2015
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 9, 597
Open AccessChemoprevention studies within lung cancer screening programmes
Ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epide